FDA approves lenalidomide/rituximab for indolent non-hodgkin lymphoma
The FDA has approved the R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) for use in patients with previously treated follicular lymphoma and marginal zone lymphoma (MZL). The double-blind, phase III AUGMENT trial included 358 patients with relapsed/refractory follicular lymphoma or MZL in need of treatment.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063